PegBio Co., Ltd. (HKG:2565)
Hong Kong · Delayed Price · Currency is HKD 3.075
-0.610 (-16.55%)
Nov 3, 2026, 4:08 PM HKT
PegBio Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
53
Market Cap
1.20B HKD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | 242.40K | 133.56K | 122.72% |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Hangzhou Jiuyuan Genetic Biopharmaceutical | 1.50B |
| AIM Vaccine | 1.16B |
| Mabpharm | 888.77M |
| Shandong Boan Biotechnology | 720.87M |
| Antengene Corporation | 652.54M |
| Guangzhou Innogen Pharmaceutical Group | 176.96M |
| ImmuneOnco Biopharmaceuticals (Shanghai) | 170.32M |
| Beijing Biostar Pharmaceuticals | 63.74M |
PegBio News
- 2 months ago - PegBio Quarterly report: H1 2026 - Filings
- 2 months ago - PegBio Earnings release: H1 2026 - Filings
- 7 months ago - PegBio Annual report: H2 2025 - Filings
- 7 months ago - PegBio Earnings release: H2 2025 - Filings